We are a bio venture company from RIKEN, Japan (RIKEN), a major global think tank. We developed a novel cancer treatment method "RIKNKT" with minimal invasion (few overall events disturb the homeostasis in vivo due to external factors) and almost no side effect, that uses cells with intense antitumor effect researched by RIKEN and many other medical institutions. Since June 2008, we have begun offering it at private medical institutions under legal procedures in the regenerative medicine new law in Japan.
As a result of medical provision, about 80% of patients were able to obtain partial remission (A state in which the cancer contracts and the symptoms are improved), complete remission(A condition in which symptoms of cancer disappear and the numerical value of examination also shows normal), and stop progress, regardless of site or stage, which verifies that it has a high response rate (the size of cancer shrinks).
Based on these results, we will spread this therapy in full scale expecting that as many patients as possible can receive treatment from now on while cancer patients are increasing. At the same time, we will further advance our technology development. Additionally, we will continue our drug discovery business to acquire drug approval.
This offer is based solely on information provided by the offeror and other publicly available sources.
The token sale or exchange event is completely independent of ICOholder. ICOholder is not involved in any way, including technical support or promotion.
We list token sales from entities with which we have no relationship to help users track overall activity within the token sector. This information is not intended as advice, and you should seek professional or specialist guidance or conduct your own due diligence before making any decisions based on our content.
Any terms and conditions regarding token acquisition are solely between contributors and the token issuer. ICOholder is not the seller of these tokens.
ICOholder is not legally responsible for any representations made by third parties about any token sale. Any claims for breach of contract must be directed against the listed token issuing entity.
If you have concerns about the nature, legality, or propriety of a token sale or the involved individuals, please contact info@icoholder.com with detailed information.